TBPH Stock Overview
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for TBPH from our risk checks.
Theravance Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.20 |
| 52 Week High | US$11.98 |
| 52 Week Low | US$8.21 |
| Beta | 0.35 |
| 1 Month Change | 3.95% |
| 3 Month Change | -2.85% |
| 1 Year Change | -20.21% |
| 3 Year Change | -57.86% |
| 5 Year Change | -60.87% |
| Change since IPO | -59.93% |
Recent News & Updates
Recent updates
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Theravance Biopharma EPS misses by $0.16, misses on revenue
May 04Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why
Apr 21Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
Mar 13Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value
Mar 08Shareholder Returns
| TBPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.0% | -2.3% | -3.7% |
| 1Y | -20.2% | 11.4% | 20.2% |
Return vs Industry: TBPH underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: TBPH underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| TBPH volatility | |
|---|---|
| TBPH Average Weekly Movement | 5.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TBPH has not had significant price volatility in the past 3 months.
Volatility Over Time: TBPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 99 | Rick Winningham | www.theravance.com |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company’s product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma.
Theravance Biopharma, Inc. Fundamentals Summary
| TBPH fundamental statistics | |
|---|---|
| Market cap | US$446.75m |
| Earnings (TTM) | -US$55.19m |
| Revenue (TTM) | US$57.42m |
7.8x
P/S Ratio-8.1x
P/E RatioIs TBPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBPH income statement (TTM) | |
|---|---|
| Revenue | US$57.42m |
| Cost of Revenue | US$40.62m |
| Gross Profit | US$16.80m |
| Other Expenses | US$72.00m |
| Earnings | -US$55.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 29.26% |
| Net Profit Margin | -96.11% |
| Debt/Equity Ratio | 0% |
How did TBPH perform over the long term?
See historical performance and comparison